To study the duration of antibody persistence and protection provided by the hepatitis B vaccine, we followed 773 homosexual men for five years after completion of vaccination. Among the 635 participants in whom antibody levels above 9.9 sample ratio units (SRU) developed after vaccination, 15 percent lost antibody altogether, and in another 27 percent, antibody levels declined below 10 SRU within five years. The extent of the maximal antibody response strongly predicted the persistence of protective antibody. Hepatitis B infection occurred in 55 men; 8 of these infections were clinically important (characterized by the presence of the hepatitis B surface antigen and elevation of liver-enzyme levels), and two of the patients became hepatitis B virus carriers. The long-term risk of hepatitis B infection was inversely related to the maximal antibody response to vaccine. Most severe infections occurred among those who responded poorly or had no response to the vaccination. The risk of late infection with hepatitis B in those with an initially adequate vaccine response increased markedly when antibody levels decreased below 10 SRU, but only 1 of 34 late infections resulted in viremia and liver inflammation. A second series of vaccinations induced a moderate antibody response in 50 percent of the subjects who initially had no response or a poor response; however, the persistence of antibody was poor. Both antibody loss and the risk of severe disease should be considered when booster-dose strategies for the hepatitis B vaccine are being designed.
This article has been cited by other articles:
Kim, H N, Harrington, R D, Crane, H M, Dhanireddy, S, Dellit, T H, Spach, D H
(2009). Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS
20: 595-600
[Abstract][Full Text]
Kim, H N., Harrington, R. D, Rompaey, S. E V., Kitahata, M. M
(2008). Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS
19: 600-604
[Abstract][Full Text]
Lee, C., Gong, Y., Brok, J., Boxall, E. H, Gluud, C.
(2006). Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ
332: 328-336
[Abstract][Full Text]
McMahon, B. J., Bruden, D. L., Petersen, K. M., Bulkow, L. R., Parkinson, A. J., Nainan, O., Khristova, M., Zanis, C., Peters, H., Margolis, H. S.
(2005). Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up. ANN INTERN MED
142: 333-341
[Abstract][Full Text]
Karayiannis, P., Main, J., Thomas, H. C.
(2004). Hepatitis vaccines. Br Med Bull
70: 29-49
[Full Text]
Bel'eed, K, Wright, M, Eadington, D, Farr, M, Sellars, L
(2002). Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad. Med. J.
78: 538-540
[Abstract][Full Text]
Garcia-Navarro, R., Blanco-Urgoiti, B., Berraondo, P., Sanchez de la Rosa, R., Vales, A., Hervas-Stubbs, S., Lasarte, J. J., Borras, F., Ruiz, J., Prieto, J.
(2001). Protection against Woodchuck Hepatitis Virus (WHV) Infection by Gene Gun Coimmunization with WHV Core and Interleukin-12. J. Virol.
75: 9068-9076
[Abstract][Full Text]
Kong, Q., Richter, L., Yang, Y. F., Arntzen, C. J., Mason, H. S., Thanavala, Y.
(2001). Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA
10.1073/pnas.191617598v1
[Abstract][Full Text]
Mahoney, F. J.
(1999). Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection. Clin. Microbiol. Rev.
12: 351-366
[Abstract][Full Text]
Losonsky, G. A., Wasserman, S. S., Stephens, I., Mahoney, F., Armstrong, P., Gumpper, K., Dulkerian, S., West, D. J., Gewolb, I. H.
(1999). Hepatitis B Vaccination of Premature Infants: A Reassessment of Current Recommendations for Delayed Immunization. Pediatrics
103: 14e-14
[Abstract][Full Text]
Triyatni, M., Jilbert, A. R., Qiao, M., Miller, D. S., Burrell, C. J.
(1998). Protective Efficacy of DNA Vaccines against Duck Hepatitis B Virus Infection. J. Virol.
72: 84-94
[Abstract][Full Text]
Lemon, S. M., Thomas, D. L.
(1997). Vaccines to Prevent Viral Hepatitis. NEJM
336: 196-204
[Full Text]
SHAPIRO, C. N., TOKARS, J. I., CHAMBERLAND, M. E.
(1996). Use of the Hepatitis-B Vaccine and Infection with Hepatitis B and C among Orthopaedic Surgeons. JBJS
78: 1791-1800
[Abstract][Full Text]
Bock, H. L., Kruppenbacher, J., Sanger, R., Hobel, W., Clemens, R., Jilg, W.
(1996). Immunogenicity of a Recombinant Hepatitis B Vaccine in Adults. Arch Intern Med
156: 2226-2231
[Abstract]
Wood, D. L., Rosenthal, P., Scarlata, D.
(1995). California Pediatricians' Knowledge of and Response to Recommendations for Universal Infant Hepatitis B Immunization. Arch Pediatr Adolesc Med
149: 769-773
[Abstract]
Roome, A. J., Walsh, S. J., Cartter, M. L., Hadler, J. L.
(1993). Hepatitis B Vaccine Responsiveness in Connecticut Public Safety Personnel. JAMA
270: 2931-2934
[Abstract]
Wood, R. C., MacDonald, K. L., White, K. E., Hedberg, C. W., Hanson, M., Osterholm, M. T.
(1993). Risk Factors for Lack of Detectable Antibody Following Hepatitis B Vaccination of Minnesota Health Care Workers. JAMA
270: 2935-2939
[Abstract]
Gardner, P., Schaffner, W.
(1993). Immunization of Adults. NEJM
328: 1252-1258
[Full Text]
Krahn, M., Detsky, A. S.
(1993). Should Canada and the United States Universally Vaccinate Infants against Hepatitis B?: A Cost - Effectiveness Analysis. Med Decis Making
13: 4-20
[Abstract]
Niu, M. T., Targonski, P. V., Stoll, B. J., Albert, G. P., Margolis, H. S.
(1992). Prevention of Perinatal Transmission of the Hepatitis B Virus: Outcome of Infants in a Community Prevention Program. Arch Pediatr Adolesc Med
146: 793-796
[Abstract]
Davis, J. M., Demling, R. H., Lewis, F. R., Hoover, E., Waymack, J. P.
(1992). The Surgical Infection Society's Policy on Human Immunodeficiency Virus and Hepatitis B and C Infection: The Ad Hoc Committee on Acquired Immunodeficiency Syndrome and Hepatitis. Arch Surg
127: 218-221
[Abstract]
Nagafuchi, S., Kashiwagi, S., Okada, K., Anzai, K., Nakamura, M., Nishimura, Y., Sasazuki, T., Niho, Y.
(1991). Reversal of Nonresponders and Postexposure Prophylaxis by Intradermal Hepatitis B Vaccination in Japanese Medical Personnel. JAMA
265: 2679-2683
[Abstract]
Halliday, M. L., Rankin, J. G., Bristow, N. J., Coates, R. A., Corey, P. N. J., Strickler, A. C.
(1990). A Randomized Double-blind Clinical Trial of a Mammalian Cell-Derived Recombinant DNA Hepatitis B Vaccine Compared With a Plasma-Derived Vaccine. Arch Intern Med
150: 1195-1200
[Abstract]
Clarke, J. A., Hollinger, F. B., Lewis, E., Russell, L. A., Miller, C. H., Huntley, A., Flynn, N. M.
(1989). Intradermal Inoculation With Heptavax-B: Immune Response and Histologic Evaluation of Injection Sites. JAMA
262: 2567-2571
[Abstract]
Regan, L. S.
(1989). Screening for Hepatocellular Carcinoma in High-Risk Individuals: A Clinical Review. Arch Intern Med
149: 1741-1744
[Abstract]
Mannucci, P. M., Zanetti, A. R., Gringeri, A., Tanzi, E., Morfini, M., Messori, A., Tirindelli, M. C., Biasi, R. D., Ciavarella, N., Colombo, M.
(1989). Long-term Immunogenicity of a Plasma-Derived Hepatitis B Vaccine in HIV Seropositive and HIV Seronegative Hemophiliacs. Arch Intern Med
149: 1333-1337
[Abstract]
Wainwright, R. B., McMahon, B. J., Bulkow, L. R., Hall, D. B., Fitzgerald, M. A., Harpster, A. P., Hadler, S. C., Lanier, A. P., Heyward, W. L.
(1989). Duration of Immunogenicity and Efficacy of Hepatitis B Vaccine in a Yupik Eskimo Population. JAMA
261: 2362-2366
[Abstract]
Odaka, N., Eldred, L., Cohn, S., Munoz, A., Fields, H. A., Fox, R., Solomon, R., Kaslow, R., Polk, B. F.
(1988). Comparative Immunogenicity of Plasma and Recombinant Hepatitis B Virus Vaccines in Homosexual Men. JAMA
260: 3635-3637
[Abstract]
Hadler, S. C.
(1988). Hepatitis B Prevention and Human Immunodeficiency Virus (HIV) Infection. ANN INTERN MED
109: 92-94
[Abstract]
Collier, A. C., Corey, L., Murphy, V. L., Handsfield, H. H.
(1988). Antibody to Human Immunodeficiency Virus (HIV) and Suboptimal Response to Hepatitis B Vaccination. ANN INTERN MED
109: 101-105
[Abstract]
WILLIAMS, W. W., HICKSON, M. A., KANE, M. A., KENDAL, A. P., SPIKA, J. S., HINMAN, A. R.
(1988). Immunization Policies and Vaccine Coverage Among Adults: The Risk for Missed Opportunities. ANN INTERN MED
108: 616-625
[Abstract]
HADLER, S. C.
(1988). Are Booster Doses of Hepatitis B Vaccine Necessary?. ANN INTERN MED
108: 457-458
[Abstract]
HOROWITZ, M. M., ERSHLER, W. B., MCKINNEY, W. P., BATTIOLA, R. J.
(1988). Duration of Immunity After Hepatitis B Vaccination: Efficacy of Low-Dose Booster Vaccine. ANN INTERN MED
108: 185-189
[Abstract]
Draelos, M., Morgan, T., Schifman, R. B., Sampliner, R. E.
(1987). Significance of Isolated Antibody to Hepatitis B Core Antigen Determined by Immune Response to Hepatitis B Vaccination. JAMA
258: 1193-1195
[Abstract]
(1987). Update on Hepatitis B Prevention: Recommendations of the Immunization Practices Advisory Committee. ANN INTERN MED
107: 353-357
[Abstract]
(1987). Leads From the MMWR. JAMA
258: 437-449
Hollinger, F. B.
(1987). Hepatitis B Vaccines--to Switch or Not to Switch. JAMA
257: 2634-2636
[Abstract]
Kong, Q., Richter, L., Yang, Y. F., Arntzen, C. J., Mason, H. S., Thanavala, Y.
(2001). Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA
98: 11539-11544
[Abstract][Full Text]
